Merck + Co., Inc.

Panmira Pharmaceuticals, LLC

Amira Pharmaceuticals, Inc.

Other

Merck Frosst Canada & Co.

Petpiboon Peppi Prasit

John Howard Hutchinson

Nicholas Simon Stock

Mark Moran

Jillian Frances Evans

Benito Munoz

Jeannie M Arruda

Jasmine Eleanor Zunic

Nicholas D Smith

Brian Andrew Stearns

Jeffrey Roger Roppe

Yiwei Li

Mustapha Haddach

Nicholas D P Cosford

Joseph E Payne

Dehua Huang

Cheuk K Lau

Michel Therien

Brian Walter Eastman

Lida R Tehrani

Thomas S Reger

Eduardo Setti

Brian T Campbell

Rohan V Mendonca

Chixu Chen

Renata Marcella Oballa

Osamu Okamoto

Chun-Sing Li

Joel S Robichaud

Shankar Venkatraman

Renata Oballa

Robert M Rydzewski

Dan-Xiong Wang

Elise Isabel

Jean-Pierre Falgueyret

Naomi Burke Anker

Tao Hu

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

5-lipoxygenase-activating protein (FLAP) inhibitors

A method for treating a human comprises administering a therapeutically effective amount of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, to the human in need.

5-lipdxygenase-activating protein (FLAP) inhibitors

Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5

Disclosed are prodrugs of (2R)-2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had a stroke, or are at risk of stroke, by administering the compounds or compositions of the invention.

Prodrugs of (2R)-2-propyloctanoic acid for the treatment of stroke

6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other.

[object Object]

The present invention encompasses compounds of Formula I (I) or pharmaceutically acceptable salts thereof, wherein A is the base molecule of a propionic acid or acetic acid NSAID, or a derivative thereof, X is &#x2014;COH, 1H-tetrazol-5-yl or 2H-tetrazol-5-yl and Rand Rare each independently selected from the group consisting of: Calkyl and Ccycloalkyl, as well as pharmaceutical composition comprising said compounds and methods of using said compounds. The compounds of the present invention lower the level of A&#x3b2;and are therefore useful for preventing, delaying or reversing the progression of Alzheimer's Disease.

Geminally di-substituted NSAID derivatives as A&#x3b2;42 lowering agents

Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor&#x2014;subtype 5 ('mGluR5') modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.

Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Cathepsin cysteine protease inhibitors

Compounds and compositions as protease inhibitors

Pyrones as inhibitors of cyclooxygenase-2

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Petpiboon Peppi Prasit